|
Mar 28
|
Pulse Biosciences Announces Plans to Initiate a Rights Offering
|
|
Mar 14
|
Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024
|
|
Mar 8
|
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System
|
|
Jan 31
|
Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium
|
|
Jan 2
|
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp
|
|
Dec 3
|
Executive Chairman of Pulse Biosciences Robert Duggan Buys More Stock
|
|
Nov 18
|
Chief Strategy Officer of Pulse Biosciences Picks Up 24% More Stock
|
|
Nov 15
|
Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
|
|
Nov 14
|
Pulse Biosciences, Inc. (NASDAQ:PLSE) Q3 2023 Earnings Call Transcript
|
|
Nov 14
|
Q3 2023 Pulse Biosciences Inc Earnings Call
|
|
Nov 13
|
Pulse Biosciences Inc (PLSE) Reports Decrease in Q3 Losses and Advances in Cardiac Device ...
|
|
Nov 13
|
Pulse Biosciences Reports Business Updates and Third Quarter 2023 Financial Results
|
|
May 1
|
Pulse Biosciences Announces $65 Million Private Placement
|
|
Apr 27
|
Pulse Biosciences Schedules First Quarter 2023 Financial Results Conference Call for May 11, 2023
|